Arrowhead Pharmaceuticals Q1 Results Didn't Matter -- but Its Pipeline Update Did

Arrowhead Pharmaceuticals (NASDAQ: ARWR) ranked as one of the biggest biotech winners in 2019, racking up a gain of 410%. The stock has given up some of those gains in 2020 so far, though.

But a rebound could now be on the way. Arrowhead announced its fiscal 2020 first-quarter results after the market closed on Wednesday. Here are the highlights from the company's Q1 update.

Image source: Getty Images.

Continue reading

Source Fool.com